NEUROCRINE BIOSCIENCES INC Increase (Decrease) in Accounts Receivable
NEUROCRINE BIOSCIENCES INC (NBIX) reported Increase (Decrease) in Accounts Receivable of $165.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $84.30M, a 5.77% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $81.40M, a 120.60% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$38.40M.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $132.30M, a 925.58% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in accounts receivable for fiscal 2025 was $210.50M, a 428.89% increase from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in accounts receivable for fiscal 2024 was $39.80M, a 55.43% decline from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in accounts receivable for fiscal 2023 was $89.30M, a 44.94% decline from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in accounts receivable for fiscal 2022 was $162.20M, a 471.13% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 3 month as first filed | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 6 month as first filed | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 9 month as first filed | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $84.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $165.70M 10-Q · filed 2026-07-31 | $127.30M derived: sum of 3 quarters · filed 2026-07-31 | $259.60M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | $81.40M 10-Q · filed 2026-05-05 | $43.00M derived: sum of 2 quarters · filed 2026-05-05 | $175.30M derived: sum of 3 quarters · filed 2026-05-05 | $255.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | -$38.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $93.90M derived: sum of 2 quarters · filed 2026-02-11 | $173.60M derived: sum of 3 quarters · filed 2026-07-31 | $210.50M 10-K · filed 2026-02-11 | ||||
| 2025-09-30 | $132.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $212.00M derived: sum of 2 quarters · filed 2026-07-31 | $248.90M 10-Q · filed 2025-10-28 | $246.90M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | $79.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $116.60M 10-Q · filed 2026-07-31 | $114.60M derived: sum of 3 quarters · filed 2026-07-31 | $127.50M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | $36.90M 10-Q · filed 2026-05-05 | $34.90M derived: sum of 2 quarters · filed 2026-05-05 | $47.80M derived: sum of 3 quarters · filed 2026-05-05 | $65.40M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $10.90M derived: sum of 2 quarters · filed 2026-02-11 | $28.50M derived: sum of 3 quarters · filed 2026-02-11 | $39.80M 10-K · filed 2026-02-11 | ||||
| 2024-09-30 | $12.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $30.50M derived: sum of 2 quarters · filed 2025-10-28 | $41.80M 10-Q · filed 2025-10-28 | $63.20M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-06-30 | $17.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $28.90M 10-Q · filed 2025-07-30 | $50.30M derived: sum of 3 quarters · filed 2026-02-11 | $80.70M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-03-31 | $11.30M 10-Q · filed 2025-05-05 | $32.70M derived: sum of 2 quarters · filed 2026-02-11 | $63.10M derived: sum of 3 quarters · filed 2026-02-11 | $58.90M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2023-12-31 | $21.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $51.80M derived: sum of 2 quarters · filed 2026-02-11 | $47.60M derived: sum of 3 quarters · filed 2026-02-11 | $89.30M 10-K · filed 2026-02-11 | ||||
| 2023-09-30 | $30.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $26.20M derived: sum of 2 quarters · filed 2024-10-30 | $67.90M 10-Q · filed 2024-10-30 | $114.40M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2023-06-30 | -$4.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $37.50M 10-Q · filed 2024-08-01 | $84.00M derived: sum of 3 quarters · filed 2025-02-10 | $106.20M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2023-03-31 | $41.70M 10-Q · filed 2024-05-01 | $88.20M derived: sum of 2 quarters · filed 2025-02-10 | $110.40M derived: sum of 3 quarters · filed 2025-02-10 | $125.90M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2022-12-31 | $46.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $68.70M derived: sum of 2 quarters · filed 2025-02-10 | $84.20M derived: sum of 3 quarters · filed 2025-02-10 | $162.20M 10-K · filed 2025-02-10 | ||||
| 2022-09-30 | $22.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $37.70M derived: sum of 2 quarters · filed 2023-10-31 | $115.70M 10-Q · filed 2023-10-31 | $137.40M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2022-06-30 | $15.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $93.50M 10-Q · filed 2023-08-01 | $115.20M derived: sum of 3 quarters · filed 2024-02-09 | $120.50M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2022-03-31 | $78.00M 10-Q · filed 2023-05-03 | $99.70M derived: sum of 2 quarters · filed 2024-02-09 | $105.00M derived: sum of 3 quarters · filed 2024-02-09 | $115.70M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2021-12-31 | $21.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $27.00M derived: sum of 2 quarters · filed 2024-02-09 | $37.70M derived: sum of 3 quarters · filed 2024-02-09 | $28.40M 10-K · filed 2024-02-09 | ||||
| 2021-09-30 | $5.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $16.00M derived: sum of 2 quarters · filed 2022-11-01 | $6.70M 10-Q · filed 2022-11-01 | $6.90M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-06-30 | $10.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.40M 10-Q · filed 2022-08-04 | $1.60M derived: sum of 3 quarters · filed 2023-02-09 | $10.10M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-03-31 | -$9.30M 10-Q · filed 2022-05-04 | -$9.10M derived: sum of 2 quarters · filed 2023-02-09 | -$600.00K derived: sum of 3 quarters · filed 2023-02-09 | -$900.00K derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2020-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $8.70M derived: sum of 2 quarters · filed 2023-02-09 | $8.40M derived: sum of 3 quarters · filed 2023-02-09 | $30.50M 10-K · filed 2023-02-09 | ||||
| 2020-09-30 | $8.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $8.20M derived: sum of 2 quarters · filed 2021-11-01 | $30.30M 10-Q · filed 2021-11-01 | $41.60M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2020-06-30 | -$300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $21.80M 10-Q · filed 2021-08-03 | $33.10M derived: sum of 3 quarters · filed 2022-02-11 | $51.90M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2020-03-31 | $22.10M 10-Q · filed 2021-05-05 | $33.40M derived: sum of 2 quarters · filed 2022-02-11 | $52.20M derived: sum of 3 quarters · filed 2022-02-11 | $75.60M derived: sum of 4 quarters · filed 2022-02-11 | ||||
| 2019-12-31 | $11.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-11 | $30.10M derived: sum of 2 quarters · filed 2022-02-11 | $53.50M derived: sum of 3 quarters · filed 2022-02-11 | $69.20M 10-K · filed 2022-02-11 | $69.17M 10-K · filed 2020-02-07 | |||
| 2019-09-30 | $18.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $42.20M derived: sum of 2 quarters · filed 2020-11-09 | $57.90M 10-Q · filed 2020-11-09 | $57.91M 10-Q · filed 2019-11-04 | $59.56M derived: sum of 4 quarters · filed 2021-02-05 | |||
| 2019-06-30 | $23.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | $39.10M 10-Q · filed 2020-08-03 | $39.12M 10-Q · filed 2019-07-29 | $40.76M derived: sum of 3 quarters · filed 2021-02-05 | $52.68M derived: sum of 4 quarters · filed 2021-02-05 | |||
| 2019-03-31 | $15.70M 10-Q · filed 2020-05-06 | $15.72M 10-Q · filed 2019-04-29 | $17.36M derived: sum of 2 quarters · filed 2021-02-05 | $29.28M derived: sum of 3 quarters · filed 2021-02-05 | $27.30M derived: sum of 4 quarters · filed 2021-02-05 | |||
| 2018-12-31 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-05 | $13.58M derived: sum of 2 quarters · filed 2021-02-05 | $11.60M derived: sum of 3 quarters · filed 2021-02-05 | $25.10M 10-K · filed 2021-02-05 | $25.11M 10-K · filed 2019-02-08 | |||
| 2018-09-30 | $11.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $9.94M derived: sum of 2 quarters · filed 2019-11-04 | $23.44M 10-Q · filed 2019-11-04 | $22.97M 10-Q · filed 2018-11-05 | $24.75M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-06-30 | -$1.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | $11.52M 10-Q · filed 2019-07-29 | $12.83M derived: sum of 3 quarters · filed 2020-02-07 | $36.57M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2018-03-31 | $13.50M 10-Q · filed 2019-04-29 | $14.81M derived: sum of 2 quarters · filed 2020-02-07 | $38.55M derived: sum of 3 quarters · filed 2020-02-07 | $43.84M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2017-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | $25.05M derived: sum of 2 quarters · filed 2020-02-07 | $30.35M derived: sum of 3 quarters · filed 2020-02-07 | $31.13M 10-K · filed 2020-02-07 | ||||
| 2017-09-30 | $23.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $29.04M derived: sum of 2 quarters · filed 2018-11-05 | $29.82M 10-Q · filed 2018-11-05 | $29.82M derived: sum of 4 quarters · filed 2019-02-08 | ||||
| 2017-06-30 | $5.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | $6.07M 10-Q · filed 2018-07-31 | $6.07M derived: sum of 3 quarters · filed 2019-02-08 | $6.07M derived: sum of 4 quarters · filed 2019-02-08 | ||||
| 2017-03-31 | $779.00K 10-Q · filed 2018-04-30 | $779.00K derived: sum of 2 quarters · filed 2019-02-08 | $779.00K derived: sum of 3 quarters · filed 2019-02-08 | |||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | $0.00 derived: sum of 2 quarters · filed 2019-02-08 | $0.00 10-K · filed 2019-02-08 | |||||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $0.00 10-Q · filed 2017-11-01 | ||||||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-03 | |||||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |